{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:06Z","timestamp":1790790846540,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jval.2015.08.012","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T21:08:21Z","timestamp":1445720901000},"page":"1152-1157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients"],"prefix":"10.1016","volume":"18","author":[{"given":"Andrew J.","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cicely","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Penton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhart","family":"Knerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.08.012_bib1","unstructured":"National Cancer Institute. SEER Stat fact sheets: prostate cancer. Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. [Accessed June 29, 2015]"},{"key":"10.1016\/j.jval.2015.08.012_bib2","unstructured":"Cancer Research UK. Prostate cancer incidence. Available from: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer#heading-Zero. [Accessed July 30, 2015]."},{"key":"10.1016\/j.jval.2015.08.012_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2015.08.012_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","article-title":"Drug resistance in metastatic castration-resistant prostate cancer","volume":"8","author":"Seruga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2015.08.012_bib5","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3747\/co.v17i0.718","article-title":"Current management of castrate-resistant prostate cancer","volume":"17","author":"Hotte","year":"2010","journal-title":"Cur Oncol"},{"key":"10.1016\/j.jval.2015.08.012_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1209096","article-title":"For the COU-AA-302 Investigators. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2015.08.012_bib7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","article-title":"Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial","volume":"14","author":"Basch","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2015.08.012_bib8","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: http:\/\/publications.nice.org.uk\/pmg9. [Accessed November 26, 2014]."},{"key":"10.1016\/j.jval.2015.08.012_bib9","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition] 2006. Available from: http:\/\/www.cadth.ca\/media\/pdf\/186_EconomicGuidelines_e.pdf. [Accessed November 26, 2014]."},{"key":"10.1016\/j.jval.2015.08.012_bib10","unstructured":"Mittmann N, Evans WK, Rocchi A, et al. Addendum to CADTH\u2019s guidelines for the economic evaluation of health technologies: specific guidance for oncology products 2009. Available from: http:\/\/www.cadth.ca\/en\/publication\/953. [Accessed November 26, 2014]."},{"key":"10.1016\/j.jval.2015.08.012_bib11","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/j.juro.2013.02.274","article-title":"Cabazitaxel for metastatic castration resistant prostate cancer (MCRPC): final quality of life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279)","volume":"189","author":"Bahl","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.jval.2015.08.012_bib12","doi-asserted-by":"crossref","first-page":"A430","DOI":"10.1016\/j.jval.2012.08.2156","article-title":"Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients","volume":"15","author":"Diels","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib13","doi-asserted-by":"crossref","first-page":"A431","DOI":"10.1016\/j.jval.2012.08.2158","article-title":"Impact of bone metastases on quality of life in patients with castration-resistant prostate cancer (CRPC) at high risk for developing bone metastases","volume":"15","author":"Hechmati","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib14","doi-asserted-by":"crossref","first-page":"A457","DOI":"10.1016\/j.jval.2011.08.1229","article-title":"EQ-5D utility index in patients with metastatic castration-resistant prostate cancer (MCRPC) with progression during or after first-line docetaxel therapy","volume":"14","author":"James","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib15","doi-asserted-by":"crossref","first-page":"A242","DOI":"10.1016\/j.jval.2011.08.060","article-title":"Mapping FACT-P to county-specific patient health status measured by EQ-5D in metastatic castrate resistant prostate cancer patients","volume":"14","author":"Spencer","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/sj.bjc.6601654","article-title":"A population-based study of pain and quality of life during the year before death in men with prostate cancer","volume":"90","author":"Sandblom","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jval.2015.08.012_bib17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11136-006-9156-2","article-title":"Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer","volume":"46","author":"Sullivan","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2015.08.012_bib18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/0284186X.2012.760848","article-title":"Health-related quality of life in prostate cancer","volume":"52","author":"Torvinen","year":"2013","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.jval.2015.08.012_bib19","doi-asserted-by":"crossref","first-page":"A431","DOI":"10.1016\/j.jval.2012.08.2160","article-title":"Quality of life among German patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Wolff","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"Euroqol \u2013 a new facility for the measurement of health related quality of life","volume":"16","year":"1990","journal-title":"Health Pol"},{"key":"10.1016\/j.jval.2015.08.012_bib21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jval.2011.01.004","article-title":"Deriving a preference-based measure for cancer using the EORTC QLQ-C30","volume":"14","author":"Rowen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ajco.12193","article-title":"Challenges in the sequencing of therapies for the management of metastatic canstration-resistant prostate cancer","volume":"10","author":"Parente","year":"2014","journal-title":"Asia-Pac J Clin Oncol"},{"key":"10.1016\/j.jval.2015.08.012_bib23","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Sing"},{"key":"10.1016\/j.jval.2015.08.012_bib24","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2015.08.012_bib25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-642-83419-6_27","article-title":"A modular approach to quality-of-life assessment in cancer clinical trials","volume":"111","author":"Aaronson","year":"1988","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.jval.2015.08.012_bib27","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2015.08.012_bib28","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"1999"},{"key":"10.1016\/j.jval.2015.08.012_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jval.2012.08.2201","article-title":"Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer","volume":"15","author":"Rowen","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.012_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non-small cell lung cancer","volume":"21","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2015.08.012_bib31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515020513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515020513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T03:10:01Z","timestamp":1653361801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515020513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1098301515020513"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.08.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}